Therapeutic agents

Abstract

The use of compounds that are antagonists of the pain enhancing effects of E-type prostaglandins for the treatment or prevention of neuropathic pain are described. The use of a compound that is an antagonist of the pain enhancing effects of E-type prostaglandins in the production of a medicament for use in the treatment or prevention of neuropathic pain, and a method of treating or preventing neuropathic pain by administration of an effective amount of an antagonist of the pain enhancing effects of E-type prostaglandins to a warm blooded animal such as man are also described.

What is claimed is:  
     
         1 . The use of a compound that is an antagonist of the pain enhancing effects of E-type prostaglandins, or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, for the manufacture of a medicament for use in the treatment or prevention of neuropathic pain.  
     
     
         2 . The use of a compound selected from: 
 6-[N-(2-benzyloxy-5-bromobenzyl)-N-ethylamino]pyridazine-3-carboxylic acid;    6-[N-(5-bromo-2-(2-methylprop-2-en-1-yloxy)benzyl)-N-ethylamino]pyridazine-3-carboxylic acid;    N-propanesulphonyl-6-[N-(5-bromo-2-(cyclopropylmethoxy)benzyl)-N-ethylamino]pyridazine-3-carboxamide;    N-(3,5-dimethylisoxazol-4-ylsulphonyl)-6-[n-(5-chloro-2-(2-methylpropoxy)benzyl)-nethylamino]pyridazine-3-carboxamide; and    6-[N-(5-bromo-2-(cyclopropylmethoxy)benzyl)-N-ethylamino]pyridazine-3-carboxylic acid;    or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof for the manufacture of a medicament for use in the treatment or prevention of neuropathic pain.    
     
     
         3 . The use of N-propanesulphonyl-6-[N-(5-bromo-2-(cyclopropylmethoxy)benzyl)-N-ethylamino]pyridazine-3-carboxamide or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof for the manufacture of a medicament for use in the treatment or prevention of neuropathic pain.  
     
     
         4 . A pharmaceutical composition which comprises an antagonist of the pain enhancing effects of E-type prostaglandins or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, in association with a pharmaceutically acceptable excipient or carrier for the treatment or prevention of neuropathic pain.  
     
     
         5 . A method of treating or preventing neuropathic pain in a warm blooded animal such as a human being requiring such treatment which comprises administering to said animal a therapeutically effective amount of an antagonist of the pain enhancing effects of E-type prostaglandins, or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.  
     
     
         6 . A method of treating or preventing neuropathic pain in a warm blooded animal such as a human being requiring such treatment which comprises administering to said animal a therapeutically effective amount of a compound selected from: 
 6-[N-(2-benzyloxy-5-bromobenzyl)-N-ethylamino]pyridazine-3-carboxylic acid;    6-[N-(5-bromo-2-(2-methylprop-2-en-1-yloxy)benzyl)-N-ethylamino]pyridazine-3-carboxylic acid;    N-propanesulphonyl-6-[N-(5-bromo-2-(cyclopropylmethoxy)benzyl)-N-ethylamino]pyridazine-3-carboxamide;    N-(3,5-dimethylisoxazol-4-ylsulphonyl)-6-[N-(5-chloro-2-(2-methylpropoxy)benzyl)-N-ethylamino]pyridazine-3-carboxamide; and    6-[N-(5-bromo-2-(cyclopropylmethoxy)benzyl)-N-ethylamino]pyridazine-3-carboxylic acid;    or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.    
     
     
         7  A method of treating or preventing neuropathic pain in a warm blooded animal such as a human being requiring such treatment which comprises administering to said animal a therapeutically effective amount of N-propanesulphonyl-6-[N-(5-bromo-2-(cyclopropylmethoxy)benzyl)-N-ethylamino]pyridazine-3-carboxamide, or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.